GEN-MKT-18-7897-A
Apr 13, 2021 | Blogs, Environmental / Industrial | 0 comments
Read time: 4 minutes
Introduction to cannabis: analysis
Cannabis is a broad umbrella of classification that includes both hemp and marijuana. Check out a recent blog that lays out the definitions. This blog will focus on the common criteria we look at when conducting cannabis testing, including potency, pesticides and mycotoxins.
Potency: how do you test for it?
Based on individual state regulatory requirements in the US, the potency of commercial cannabis products must be reported. The percentage of THC is printed on cannabis product labels after being certified by a licensed cannabis testing facility. The methodology for obtaining cannabis potency values can vary based on the analytical technique and instrumentation used, which gives testing facilities options for customizing or streamlining their workflows. While marijuana potency testing can vary, hemp analysis has to be accurate, or the crop is considered cannabis and subject to federal confiscation and fines. The US, however, lacks standardized methods to assess products for potency and safety. That’s a big problem for the labs that are tasked with doing the testing. There have been many challenges in the uniformity of potency results across testing sites. Some manufacturers will go to the lab that gives them the highest potency results. Pesticides, mycotoxins and terpenes, oh my!
As states in the US struggle to set standards for testing, both consumers and retailers are becoming increasingly discerning. Because of the variability and diversity of the matrix composition of samples—which can include cannabinoids, terpenes, sugars, fatty acids and more—analyzing cannabis and hemp for pesticides can be daunting. This is especially true for high-throughput cannabis and hemp residue testing. If you want to learn more about this topic, check out our tips and tricks for pesticide residue analysis in cannabis. Stay tuned for more blogs and information on the analysis of cannabis and hemp.
RUO-MKT-18-13032-A
It is no secret that (bio)pharmaceutical research and development is complex, both scientific and regulatory processes. Here is an overview of just some of the ways SCIEX is working to support these challenges.
In a recent webinar, available on demand, scientists Luiza Chrojan and Ryan Hylands from Pharmaron, provided insights into the deployment of capillary gel electrophoresis (CGE) within cell and gene therapy. Luiza and Ryan shared purity data on plasmids used for adeno-associated virus (AAV) manufacturing and data on AAV genome integrity, viral protein (VP) purity and VP ratios using the BioPhase 8800 system.
Last year, Technology Networks hosted two webinars that featured groundbreaking research utilizing SWATH DIA (data-independent acquisition) for exposomics and metabolomics. Researchers Dr. Vinicius Verri Hernandes from the University of Vienna and Dr. Cristina Balcells from Imperial College London (ICL) demonstrated how a DIA approach can be successfully implemented in small molecule analysis using the ZenoTOF 7600 system. Their innovative approaches highlight the potential of SWATH DIA to enhance the detection and analysis of chemical exposures and metabolites, paving the way for new insights into environmental health and disease mechanisms.
Posted by
You must be logged in to post a comment.
Share this post with your network